OAOlesya Nikolaevna Abrosimova

Olesya Nikolaevna Abrosimova

*This is an algorithmically generated author record based on publicly available information.

Olesya Nikolaevna Abrosimova has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of the Technology for Producing Capsules with a Compound Extract of Oplopanax elatus, Sophora japonica, and Origanum vulgare Using a Risk-Based Approach

    by A. V. Efimov, O. N. Abrosimova, А. В. Ефимов, О. Н. Абросимова

    INTRODUCTION. The application of a risk-based approach to the development of a technology for producing hard gelatin capsules (HGC) with a compound extract allows the determination of critical process parameters and critical quality attributes, which forms the basis for creating quality management tools in the manufacture of the finished dosage form (FDF) and is consistent with the modern quality-by-design concept. AIM. Development of a technology for producing hard gelatin capsules with a compound extract of Oplopanax elatus , Sophora japonica , and Origanum vulgare using a risk-based approach to the quality of the finished dosage form. MATERIALS AND METHODS. The compound extract was obtained by concentrating a hydroalcoholic extract from a mixture of medicinal plant raw materials: roots and rhizomes of Oplopanax elatus , flower buds of Sophora japonica , and herb of Origanum vulgare . The granulate composition was developed using design of experiments. The granulate was filled into hard gelatin capsules. Standardization of the capsules was performed according to the Pharmacopoeia of the Eurasian Economic Union (EAEU) methods. Quantitative analysis of flavonoids was carried out by spectrophotometry, and qualitative analysis by thin-layer chromatography (TLC). Risk identification for capsule quality was performed using Ishikawa (fishbone) diagrams. RESULTS. A laboratory-scale technology for the thick extract of Oplopanax , Sophora , and Origanum is proposed, based on four-fold ultrasonic remaceration with 70% ethanol, dividing the extractant into portions. This method yields an extract with an average flavonoid content of 2.63±0.16%. The composition and technology of the granulate with the compound extract were developed using wet granulation with readily available excipients. The obtained granulate had an average flavonoid content of 1.85±0.04%. A laboratory technology for HGC with an average flavonoid content of 1.56±0.04% is proposed. Critical quality attributes and critical process parameters for the FDF production were identified. The thick compound extract, granulate, and hard gelatin capsules obtained by the developed technology meet the design and pharmacopeial requirements for the quality attributes tested. CONCLUSIONS. A technology for producing HGC with a compound extract of Oplopanax , Sophora , and Origanum has been developed, taking into account risk identification for FDF quality. The proposed technology is limited to the preliminary laboratory level of evaluating the parameters for HGC production. The results obtained allow further refinement of technological parameters, preparation of pilot batches, and assessment of quality risks within the framework of pharmaceutical development of the FDF.

  • Open Access

    Development of a technology for a combined hepatoprotective agent

    by I. E. Kauhova, O. N. Abrosimova, B. A. Perez, N. Y. Sipkina, E. K. Novikova, I. E. Smekhova, A. L. Marchenko

    Introduction. Hepatoprotectors are one of the broad drug groups used in complex therapy at different stages of liver damage. In clinical practice, hepatoprotective agents are used in form of individual or combined drugs. A combined drug is defined as a preparation containing two or more active biological substances that act together in the human body to prevent and treat diseases or to restore and maintain health. Combined drugs are used to increase the treatment effectiveness, reduce side effects, simplify medication intake, or help to treat multiple symptoms at the same time. Often the following well-known hepatotropic agents are most studied and used in combinations: essential phospholipids, glycyrrhizic acid, ursodeoxycholic acid and silymarin. It should be noted that although the pharmacological action of ursodeoxycholic acid and milk thistle preparations has been well studied, no technological research has been conducted to create combined medicines based on them. Aim. Development of a technology for a combined hepatoprotective agent in form of solid enteric-soluble gelatin capsules with granules containing ursodeoxycholic acid and milk thistle dry extract in form of a solid dispersion system as active substances. Material and methods. Ursodeoxycholic acid and the solid dispersion system of milk thistle dry extract are included as substances in the formulation of the combined hepatoprotective drug. Solid intestinal-soluble gelatin capsules were filled with granules containing a solid dispersion system of milk thistle dry extract and ursodeoxycholic acid using a ProFiller 3600 desktop manual capsule filling machine, capsule size "2". 3 series of solid gelatin capsules with granules were developed. The capsules standardization was carried out in accordance with the State Pharmacopoeia of the Russian Federation XV edition. The following indicators were determined: description, authenticity, quantitative content of the amount of flavolignans in terms of silybin, quantitative content of ursodeoxycholic acid, mass uniformity of dosage forms, disintegration and dissolution. Results and discussion. The granules formulation was developed by wet granulation, microcrystalline cellulose as disintegrator, magnesium stearate as lubricant, and 5 % aqueous solution of potato starch were used as excipients. The obtained formulations were compared in terms of quality and technological properties. It was found that granules containing microcrystalline cellulose have the best technological properties, such as weight loss during drying, hygroscopicity, bulk density, Carr index, Hausner coefficient, flowability. For capsules with granules, quality indicators were determined and standardized according to the POA (pharmacopeia official article) "Capsules" in terms of quality indicators: description, authenticity, quantitative content of the amount of flavonoids in terms of silybin, quantitative content of ursodeoxycholic acid, mass uniformity of dosage forms, disintegration and dissolution. When performing the "Dissolution" test, the release of silybin and UDCA was determined in 30, 45 and 60 minutes. The release of silybin was monitored by spectroscopy at a wavelength of λ = 289 nm and the release of ursodeoxycholic acid by high–performance liquid chromatography (HPLC) in accordance with the US pharmacopoeia, USP 44 – NF 39. It was determined that 89.0 ± 0.5 % of silybin was released in 45 minutes, during which time 97.0 ± 0.3 % of ursodeoxycholic acid was released. Conclusion. The granules formulation with a solid dispersion system of milk thistle dry extract and ursodeoxycholic acid has been developed. Microcrystalline cellulose is used as disintegrant, magnesium stearate as lubricant, and 5% aqueous solution of potato starch as binder. The technological properties of the granules and quality indicators are determined. The technology of intestinal-soluble capsules filled with granules has been developed. The quality indicators were determined and standardized according to quality indicators: description, authenticity, quantitative content of the amount of flavonoids in terms of silybin (by UV spectroscopy), quantitative content of ursodeoxycholic acid (by HPLC), mass uniformity of dosage forms, disintegration and dissolution. The releasing profiles of the active pharmaceutical substance from enteric capsules were studied and it was found that 89.0 ± 0.5 % of the amount of flavolignans in terms of silybin and 97.0 ± 0.3 % of ursodeoxycholic acid were released by 45 minutes, respectively, which meets the requirements of the State Pharmacopoeia of the Russian Federation XV edition.

  • Open Access

    Development of solid dispersion system from milk thistle dry extract by solvent method

    by B. A. Perez, I. E. Kauhova, I. I. Terninko, O. N. Abrosimova, E. V. Vishnyakov, N. S. Pivovarova

    Introduction. Silymarin is one of the main components used in preparations for hepatotropic therapy. Silymarin is contained in the dry extract of seeds and fruits of milk thistle (Silybum marianum L. Gaertn.), however it has poor bioavailability due to the crystalline state and low solubility of silymarin flavolignans in water at room temperature, as well as their poor absorption. One of the methods for increasing the bioavailability of medicinal substances consists in their introducing into solid dispersion systems (SDS). The most suitable method for obtaining SDS with extracts is the solvent method, since it does not require the use of a high temperature regime during the obtaining process of SDS.Aim. To develop the technology for solid dispersion system from milk thistle dry extract by solvent method to increase the bioavailability of this phytosubstance.Material and methods. The obtaining of the solid dispersion systems from milk thistle dry extract by solvent method was carried out with polyvinylpyrrolidone (PVP K-29/32), polyvinylpyrrolidone vinyl acetate 6 : 4 (PVPVA 64), hydroxypropylmethylcellulose (HPMC), gelatin and sodium lauryl sulfate (SLS). The quality indicators of the SDS: particle size distribution, bulk density, residual humidity and hygroscopicity were carried out according to the methods of the State Pharmacopoeia of the Russian Federation (GP RF) XV edition. The quantitative determination of biologically active substances (BAS) was carried out in accordance with the GP RF XV ed. by the amount of flavolignans in terms of silybin.Results and discussion. During the development of solid dispersion systems by solvent method, SDS samples from milk thistle dry extract (MTDE) with different polymers were studied. As a result of studying the particle size distribution, several SDS samples were selected. The SDS samples were compared with the MTDE sample. The "Dissolution" test showed that the micronization of MTDE in form of SDS by solvent method, containing polyvinylpyrrolidone vinyl acetate – PVP VA 64 is the best alternative for increasing the silybin releasing-degree from the extract and increasing its bioavailability. According to the content of the sum of flavolignans in terms of silybin, the selected SDS sample meets the requirements of the normative documentation for milk thistle dry extract. In addition, the conditions for the development of SDS do not significantly affect the quantitative content of silybin compared with the content of the control sample of MTDE. The technological characteristics of SDS have been investigated and their qualitative improvement compared to the MTDE sample has been established. The interaction between the polymer carrier and the milk thistle extract was evaluated by the IR-fourier spectroscopy method.Conclusion. The SDS from milk thistle dry extract was developed by solvent method. For the developed SDS, quality indicators such as the content of the sum of flavolignans in terms of silybin, residual humidity, bulk density, particle size distribution and hygroscopicity were determined. The solid dispersion system from milk thistle extract was analyzed by IR-fourier spectroscopy. The physico-chemical compatibility between the milk thistle extract and the polymer-carrier polyvinylpyrrolidone vinyl acetate is shown. The development of the SDS from milk thistle dry extract significantly increased the bioavailability of the phytosubstance by increasing the silybin releasing-degree of the SDS by 3 times compared with the control sample of MTDE.


  • Open Access

    Development of Composition and Technology of Effervescent Tablets with Biologically Active Complex of Black Chokeberry (Aronia melanocarpa (Michx.) Elliott) Fruits

    by N. S. Pivovarova, O. N. Abrosimova, T. S. Shebitchenko, N. V. Sokrasnkina, A. A. Shmarova, E. K. Novikova, K. O. Sidorov

    Introduction. Actual use of plant raw materials in the production of medicines is caused by a variety of bioactive substance complexes in their composition. These drugs have a wide range of therapeutic effects and in this regard, the properties and compositions of various plant materials are currently being actively studied. Aronia melanocarpa (chokeberry) has been the focus of scientific research for many years to identify various healing properties, and in 2015 its fresh and dried fruits are presented as a plant raw material in the State Pharmacopoeia of the Russian Federation, XIV edition. The variety of biologically active substance complexes of Aronia melanocarpa fruit allows its use in different fields (food and pharmaceutical industries). For this reason, the development of the composition and technology of effervescent tablets containing a complex of biologically active substances and possessing the following advantages: rapid release of active ingredients, high rate of BAS assimilation, usability and pleasant flavor are of interest.Aim. The aim of the present study is to develop the composition and technology of effervescent tablets with a biologically active complex from dried Аronia melanocarpa fruits.Materials and methods. Extracts enriched with anthocyanins were obtained from dried chokeberry fruits. As excipients in the technology of effervescent tablets, sodium carbonate, tartaric acid, lactose monohydrate, povidone (Plasdone™ K-29/32), polyethylene glycol 6000 and aspartame were used. Under laboratory conditions, granules (acidic and basic) were obtained by the method of punching wet masses, where extract (granulate 1) and ethyl alcohol 96 % (granulate 2) were used as a moisturizer. Numerical indicators of medicinal plant raw materials, technological properties of granulate and tableting mass, as well as quality indicators of effervescent tablets were determined according to the methods described in the State Pharmacopoeia of the Russian Federation, XIV edition.Results and discussion. Numerical indicators of dry fruits of Aronia melanocarpa (crushing of raw materials and the content of foreign impurities, total ash in plant raw materials and ash insoluble in hydrochloric acid, content of extractives) were determined, and the good quality of the raw materials used in the subsequent stages of drug development was confirmed. An extract enriched with anthocyanins has been developed. The composition and technology of effervescent tablets with separate granulation of acidic and basic components has been developed. Extract and ethyl alcohol 96 % were used as moisturizers, and aspartame was used to improve taste characteristics. A draft specification for the quality indicators of effervescent tablets based on enriched extraction has been proposed.Conclusion. In the course of the research work, the numerical indicators of medicinal plant raw materials were determined and its quality was confirmed, which enabled its use for further extraction. Extraction conditions were chosen, extracts were obtained. Excipients have been selected, the composition and technology of effervescent tablets based on the extracts of Aronia melanocarpa fruits have been developed, a draft specification for effervescent tablets has been proposed in accordance with the requirements of the State Pharmacopoeia of the Russian Federation, XIV edition.


  • Open Access

    Obtaining Callus Culture of Sage Medicinal (Salvia officinalis L.) and its Characteristics

    by N. S. Pivovarova, T. S. Shebitchenko, O. N. Abrosimova

    Introduction. Cultivation of biomass of plant cells as a method of obtaining raw materials has existed for quite a long time. Plant cells cultivated in vitro act as a source of valuable secondary metabolites such as phenols, alkaloids, phytosteroids, glycosides, etc. It is important to create conditions under which the accumulation of valuable biologically active substances will be observed in the strains. Cultivation involves the use of complex multicomponent nutrient media containing a certain set of macro-, microelements, vitamins, growth stimulants. Salvia officinalis has a wide spectrum of pharmacological action. Due to the limited growing area of medicinal sage, as well as the deterioration of the ecological situation in the growing regions, the use of a phytobiotechnological method for obtaining raw materials is relevant.Aim. The aim of the study is to obtain a viable callus culture of salvia officinalis (Salvia officinalis L.).Materials and methods. Leaves of an intact plant sage medicinal, of the Lamiaceae family (Salvia officinalis, Lamiaceae) were used as explants. The explants were pre-sterilized with 6 % sodium hypochlorite solution for 20 minutes and 70 % ethanol for 1 minute. It was cultivated on a nutrient medium according to the Murasig – Skoog recipe. Determination of cell viability using vital dyes was assessed using microscopy (digital microscope Bresser LCD 50x-2000x, Germany). High performance thin layer chromatography was performed using a HPTLC PRO SYSTEM (CAMAG AG, Switzerland).Results and discussion. After two weeks of cultivation, the formation of primary callus was observed on the surface of the explants. Visually, it was a thin layer of intensely dividing undifferentiated light yellow cells. During cultivation, the biomass of the resulting callus increased, it became looser and acquired a darker shade, and the nutrient medium also began to darken. The detected cells during microscopy can be divided into two types: the first type is cells of the meristematic type, the second type is cells of the parenchymal type. Microscopy showed that more than 95 % of all visualized cells are alive. In the following passages, no significant changes in the morphotype of the culture were noted. In the eleventh passage, a study of the growth activity of the strain was carried out. The maximum specific growth rate of 0.42 day-1 is observed on the 14–18th day of growth, while the biomass doubling time is the smallest and corresponds to the value of 1.66 days. During one cultivation cycle, the amount of biomass increases by 7.73 times. The results of a qualitative analysis by the method of high-performance thin-layer chromatography (HTPLC) show that the qualitative composition of the biomass of medicinal sage is generally close to that of intact plants.Conclusion. A viable stable strain of plant cells of salvia officinalis was obtained on a nutrient medium according to the Murasig – Skoog recipe with a half content of micro- and macrosols and phytohormones 2,4-D (6 mg/ml) and kinetin (1 mg/ml). For the following passages, it is recommended to use a nutrient medium according to the Murasig – Skoog recipe with a full content of micro and macrosols and phytohormones naphthylacetic acid (1 mg/ml) and kinetin (1 mg/ml). The bulk of the obtained heterogeneous callus is made up of cells of the meristematic and parenchymal type. The qualitative composition of BAS biomass of medicinal sage is generally close to that of intact plants.


  • Open Access

    Risk-based Approach in Obtaining and Analysing the Characteristics of Baikal Skullcap Suspension Cultures

    by A. A. Shmarova, N. S. Pivovarova, O. N. Abrosimova

    Риск-ориентированный подход при получении и анализе свойств суспензионных культур клеток шлемника байкальского


  • Open Access

    Transfer of Cosmetic Emulsion Cream Technology from Laboratory to Pilot Phase

    by M. A. Burakova, O. N. Abrosimova, Yu. M. Ladutko, I. E. Smekhova

    Introduction. When transferring the technology of cosmetic emulsion cream from laboratory conditions to semi-industrial equipment, it is necessary to determine the critical process parameters that will allow achieving results without losing the quality of the final product.Aim. The aim of the study is to confirm the effectiveness of the developed technology for the production of emulsion cream under scaling conditions.Materials and methods. As active substances were used badan thick-leaved extract dry, salicylic acid, dimethicone, menthol and octypyrox; emollients – grape seed oil, coconut oil, castor oil; emulsifiers and co-emulsifiers – distilled monoglycerides, emulsion wax, anhydrous lanolin, Cremophor A25; humidifier – glycerin; alkaline agent, pH regulator – triethanolamine; preservative – Euxil 9010; fragrance – essential oil of rosewood, solvent – purified water. Phase mixing and emulsification were carried out in a PRS AR 403 planetary mixer (ERWEKA GmbH, Germany), dosing into a sealed plastic container was carried on an FDS II AR 403 ointment dosing unit (ERWEKA GmbH, Germany). The study of the physicochemical and structural-mechanical properties of the cream was carried out in accordance with GOST 29188.2-2014 and GOST 29188.3-91.Results and discussion. Under scaling conditions, 3 pilot series of cosmetic emulsion cream for the prevention of dry seborrhea of the scalp based of badan thick-leaved extract dry have been developed. The cream obtained both in the pilot and laboratory phases met all the requirements of the Technical Regulations of the Customs Union (TR CU) 009/2011 "On the safety of perfumery and cosmetic products", which confirms the reproducibility of the developed production technology. A 20-fold increase in loading did not affect the methods of introducing the components and their percentage. To determine the possibility of technology transfer from laboratory conditions to semi-industrial production conditions, the technological characteristics of the equipment were analyzed for the ability to carry out the required technological process, using the Ishikawa diagram, risks were identified and causal relationships of the production. The most important indicators of the technological process have been established – these are the temperature, the number of revolutions of the mixer and the mixing time.Conclusion. On the semi-industrial equipment of the GMP training center, the technology of obtaining a cosmetic emulsion cream based on badan thick-leaved extract dry. A causal diagram (Ishikawa diagram) was compiled. Taking into account possible risks in the production of emulsion cream (number of revolutions of the mixer, stirring time, temperature) made it possible to obtain a stable product that meets all the requirements of TR CU 009/2011 "On the safety of perfumery and cosmetic products". The reproducibility of the technological process is shown.


  • Open Access

    Development of Technology and Composition of the Medicinal Product for Oral Cavity Based on Phytosubstances

    by O. N. Abrosimova, N. S. Pivovarova, M. A. Burakova, T. S. Shebitchenko

    Introduction. Treatment and prevention of diseases of the oral mucosa is one of the priority tasks in dentistry. In practice, antibacterial agents are often used in the complex treatment of inflammatory and destructive processes. However, long-term, uncontrolled usage of such drugs leads to numerous complications: drug tolerance, weakening of the therapeutic effect, dysbiosis of the oral cavity and gastrointestinal tract, etc. Therefore, at present, the question of search for alternative to antibiotic therapy remains open. As an alternative, it is necessary considering the usage of effective and safe herbal medicines that are easy to digest, less toxic, practically do not cause side effects and allergic reactions, and have a light regulating and normalizing effect.Aim. The aim of the present study is to develop the composition and technology of effervescent granules for the preparation of a solution for rinsing the oral cavity based on phytosubstances.Materials and methods. Dry extracts were obtained from medicinal plant materials: medicinal sage leaves, medicinal calendula flowers, yarrow herb, medicinal rhizomes and roots and astragalus woolly herb. Sodium carbonate, citric acid, anhydrous, microcrystalline cellulose – 90 (EMCOCEL®90M), povidone (Plasdone™ K-29/32) and calcium stearate were used as auxiliary substances in the granule technology. In laboratory conditions, granules based on phytoextracts were obtained by pressing wet masses. Numerical indicators of medicinal plant raw materials, technological properties of dry extracts and granules, as well as indicators of the quality of granules were determined according to the methods described in the State Pharmacopoeia XIV.Results and discussion. The numerical indicators of medicinal plant raw materials (grinding of raw materials and the content of impurities, total ash in medicinal plant materials and ash insoluble in hydrochloric acid, humidity, content of extractives) were determined and the good quality of the raw materials used in the subsequent stages of drug development was confirmed. Dry extracts from each type of medicinal plant raw materials have been developed and the technological properties of dry extracts have been determined. The composition and technology of effervescent granules by pressing wet masses has been developed. To improve the flowability and reduce the hygroscopicity of the granulated material, microcrystalline cellulose – 90 (EMCOCEL®90M) was used as a filler. To create an effervescent dosage form, citric acid and sodium bicarbonate were added to the granules. The mass for granulation was moistened with a 10% alcohol-water solution of Plasdone™ K-29/32. A draft specification of quality indicators for effervescent granules based on phytoextracts is proposed.Conclusion. In the course of the research work, the numerical indicators of medicinal plant raw materials were determined and its quality was confirmed, which made it possible to use it for further production of dry extracts. The extraction conditions were selected for each type of raw material, dry extracts were developed, and quality indicators were determined in accordance with the requirements of the State Pharmacopoeia XIV. Excipients were selected taking into account the properties of dry extracts, the composition and technology of effervescent granules based on phytoextracts was developed, a draft specification for effervescent granules was proposed in accordance with the requirements of the State Pharmacopoeia XIV.


  • Open Access

    Scaling of the Granulation Process in the Conditions of GMP Training Center and Assessment of Possible Risks

    by O. N. Abrosimova, M. A. Burakova

    Introduction. The stage of wet granulation is often used in the technology of solids. The method of wet granulation in a mixer-granulator with high shear force can be regarded as the most complicated method of its implementation from the engineering and technological point of view. The mixer-granulator has two mixers located in mutually perpendicular planes. Using an impeller, dry components are mixed, and the chopper, turning on when spraying a humidifier, ensures the formation of granules. By setting different chopper rotational speed, granules of different sizes can be obtained. This granulator has the following advantages: it provides a high product yield (≥ 99 %), takes up small workspaces, and the closed design ensures environmental protection.Aim. The aim of the research is to scale the granulation process, on the example of the solids production technology, using the wet granulation stage - in a mixer-granulator with high shear force.Materials and methods. Dry extract «N» and auxiliary substances were used as a pharmaceutical substance: lactose monohydrate, microcrystalline cellulose (MCC) (MICROCEL® MC-102), potato starch, povidone (Plasdone™ K-29/32), calcium stearate. Granulate under scaling conditions was produced in a mixer-granulator with high shear force. Technological properties of dry extract «N» and granulate were determined by the methods described in National pharmacopeia XIV.Results and discussion. On the basis of experimental studies, it was found that the resulting granulate, both when obtained under laboratory conditions and under scaling conditions, has good flowability, and also has a homogeneous fractional composition. The presence of a grinder in the mixer-granulator made it possible to obtain a more uniform fractional composition of the granulate. A 10-fold increase in loading did not affect the composition of the granulate. When scaling the pelletizing process, a risk analysis was carried out, factors influencing the technological process were identified and structured. It turned out that the most important stages are mixing and the actual granulation. To obtain a homogeneous mixture, additional equipment was used - a mixer.Conclusion. As a result of scaling up the granulation process, the parameters of wet granulation in the mixer-granulator (optimal loading, impeller and grinder rotation frequency), technological properties of the resulting granulate, and risks affecting the technological process were selected. were evaluated and a causal diagram (Ishikawa diagram) was drawn.


  • Development of quality indicators for an ethanol infusion in a glucose solution as an antidote for surrogate alcohol poisonings

    by Maria Andreevna Grigoryeva, Olesya Nikolaevna Abrosimova, Olga Yuryevna Strelova, Tatyana Yuryevna Ilyina, Alexander Nikolaevich Grebenyuk

    Введение. Отравления алкоголем и его суррогатами постоянно регистрируются во многих странах мира, являясь одной из ведущих причин госпитализации и смертности пациентов с острыми химическими отравлениями. Однако в Реестре лекарственных средств РФ антидота, используемого для лечения отравлений суррогатами алкоголя, в настоящее время не зарегистрировано. Цель работы: разработка технологии и параметров стандартизации инфузионной формы этанола. Материал и методы. Использованы субстанция глюкозы (декстрозы), и этиловый спирт, соответствующий требованиям статьи ФС.2.1.0036.15 ГФ РФ XIV изд., для получения воды использовалась система обратного осмоса НПО «Фильтерра». Показатели качества раствора определялись с помощью устройства визуального контроля «Светлячок», рН-метра Mettler Toledo Five Easy 20 с универсальным комбинированным электродом LE438 IP67 с термодатчиком, рефрактометра лабораторного ИРФ-454Б2М и газового хроматографа «Кристаллюкс 4000М» с пламенно-ионизационным детектором, стерилизатора. Стабильность раствора определилась в термостате IB-15G (JeioTech, Корея). Для определения эффективности применения полученного раствора при острой интоксикации метиловым спиртом и этиленгликолем были использованы белые беспородные крысы-самцы с массой тела 195-314 г. Результаты. Разработаны методики качественного и количественного определения этилового спирта и глюкозы в 5% инфузионном растворе этилового спирта в 5% растворе глюкозы с добавлением стабилизатора Вейбеля. Проведена оценка стабильности препарата в условиях ускоренного старения. Установлено, что инфузионный раствор предлагаемого состава стабилен в течение всего периода эксперимента, что соответствует 3 годам хранения при комнатной температуре. Проведена первичная оценка эффективности применения инфузионного раствора этилового спирта предлагаемого состава по показателю выживаемости в экспериментальном остром отравлении суррогатами алкоголя в опытах на лабораторных животных. Заключение. Разработана технология производства 5% раствора этилового спирта в 5% растворе глюкозы. Предложены параметры стандартизации данной лекарственной формы. Установлен предполагаемый срок годности. Разработанные методики...